Folyóiratcikkek tallózása szerző szerint "Reis, H"

A találatok rendezése: Rendezés: Találatok:

  • Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer 
    Szarvas, Tibor; Sevcenco, S; Módos, Orsolya; Keresztes, Dávid; Nyirády, Péter; Kubik, András; Romics, Miklós; Kovalszky, Ilona; Reis, H; Hadaschik, B; Shariat, SF; Kramer, G (2018)
    OBJECTIVES: Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to ...
  • Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas 
    Reis, H; van der Vos, KE; Niedworok, C; Herold, T; Módos, Orsolya; Szendrői, Attila; Hager, T; Ingenwerth, M; Vis, DJ; Behrendt, MA; de Jong, J; van der Heijden, MS; Peyronnet, B; Mathieu, R; Wiesweg, M; Ablat, J; Okon, K; Tolkach, Y; Keresztes, D; Nagy, N; Bremmer, F; Gaisa, NT; Chlosta, P; Kriegsmann, J; Kovalszky, Ilona; Timár, József; Kristiansen, G; Radzun, HJ; Knuchel, R; Schuler, M; Black, P; Rubben, H; Hadaschik, B; Schmid, KW; van Rhijn, BWG; Nyirády, Péter; Szarvas, Tibor (2018)
    Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly ...
  • Urachal cancer - current concepts of a rare cancer 
    Reis, H; Szarvas, Tibor (2018)
    Urachal cancer is arare but aggressive disease. In addition to the non-glandular tumors, non-cystic urachal adenocarcinomas are nowadays distinguished from the primary cystic variant. (Immunohistochemical) markers are only ...